Sacubitril And Valsartan Tablet
Product Images NDC 72865-312

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 72865-312). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

898 (Sacubitril Valsartan 24 mg 26 mg 180)

Packaging label for Sacubitril and Valsartan Tablets, 24 mg/26 mg strength, supplied as a bottle containing 180 tablets. The label shows the product is Rx only and manufactured by XLCare Pharmaceuticals Inc. It includes storage instructions, contact information, and manufacturing addresses for XLCare Pharmaceuticals and Evaric Pharmaceuticals Inc.*

FDA Label Image

565 (Sacubitril Valsartan 24 mg 26 mg 60)

Label for Sacubitril and Valsartan Tablets 24 mg/26 mg by XLCare Pharmaceuticals Inc. The label indicates 60 film-coated tablets, prescription use only. Storage instructions and manufacturer details for XLCare and Evaric Pharmaceuticals are provided along with a barcode and contact information.*

FDA Label Image

454 (Sacubitril Valsartan 49 mg 51 mg 180)

Label for Sacubitril and Valsartan Tablets 49 mg/51 mg by XLCare Pharmaceuticals Inc. The label indicates 180 film-coated tablets, with storage instructions and manufacturer details. The label includes the NDC 72865-311-18 and states Rx only.*

FDA Label Image

151 (Sacubitril Valsartan 49 mg 51 mg 60)

Packaging label for Sacubitril and Valsartan Tablets 49 mg/51 mg by XLCare Pharmaceuticals Inc. The label indicates the product contains 60 tablets and is for prescription use only. It includes storage instructions, manufacturer details, and a barcode on the left side.*

FDA Label Image

454 (Sacubitril Valsartan 97 mg 103 mg 180)

Label of Sacubitril and Valsartan Tablets 97 mg/103 mg by XLCare Pharmaceuticals Inc. The label shows a blue and white background with a green box highlighting the strength. It specifies 180 tablets with Rx only, includes storage instructions, manufacturer details, and a barcode on the left side.*

FDA Label Image

454 (Sacubitril Valsartan 97 mg 103 mg 60)

Label for Sacubitril and Valsartan Tablets 97 mg/103 mg from XLCare Pharmaceuticals Inc. The label indicates 60 tablets in the package, Rx only. It includes storage instructions, manufacturer details, and a barcode on the side. No varnish is noted on the label.*

FDA Label Image

545 (Sacubitril Valsartan Fig 1)

A chart displaying the geometric mean ratio and 90% confidence intervals for coadministered drugs compared to reference. The x-axis indicates change relative to reference from 0.5 to 2.0. Data points for AUC and Cmax are plotted for drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*

FDA Label Image

665 (Sacubitril Valsartan Fig 2)

A pharmacokinetic comparison chart showing geometric mean ratios with 90% confidence intervals for AUC and Cmax of LBQ657 and Valsartan across different population categories including renal impairment levels, hepatic impairment, age groups, gender, and ethnicity. The x-axis represents the change relative to reference values for both AUC and Cmax.*

FDA Label Image

898 (Sacubitril Valsartan Fig 3a)

A Kaplan-Meier curve illustrating the time to first occurrence of cardiovascular death or heart failure hospitalizations in the PARADIGM-HF study. The graph compares Sacubitril and Valsartan versus Enalapril over approximately 1,260 days, displaying cumulative failure rates and number of patients at risk over time.*

FDA Label Image

212 (Sacubitril Valsartan Fig 3b)

A line chart titled "Time to Occurrence of CV Death in PARADIGM-HF" showing the cumulative failure rate (%) over time (days) since randomization, comparing Sacubitril and Valsartan with Enalapril. The chart includes a hazard ratio (HR) of 0.80 (95% CI: 0.71, 0.89) and displays the number of patients at risk at various time points for both treatments.*

FDA Label Image

554 (Sacubitril Valsartan Fig 3c)

A Kaplan-Meier curve showing the time to first occurrence of heart failure hospitalizations in the PARADIGM-HF study. It compares cumulative failure rates over approximately 1,260 days for patients treated with Sacubitril and Valsartan versus Enalapril. The chart includes the number of patients at risk over time and a hazard ratio (HR) with 95% confidence interval (CI).*

FDA Label Image

565 (Sacubitril Valsartan Fig 4)

A data table with a forest plot showing hazard ratios (95% CI) comparing Sacubitril and Valsartan versus Enalapril across various subgroups such as age, gender, weight, race, region, NYHA class, estimated glomerular filtration rate, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior use of ACE inhibitors, ARBs, aldosterone antagonists, prior heart failure hospitalization, time since diagnosis, cause of heart failure, and ICD use. The table details percentage of total population, event numbers, and hazard ratios along with confidence intervals.*

FDA Label Image

989 (Sacubitril Valsartan Fig 5)

A line graph depicting the mean number of heart failure hospitalizations and cardiovascular deaths per 100 patients over time in days since randomization in the PARAGON-HF study. Two lines compare outcomes for patients taking Valsartan versus Sacubitril and Valsartan, with event counts increasing over approximately 1440 days. Patient numbers at risk at various time points are indicated below the x-axis.*

FDA Label Image

565 (Sacubitril Valsartan Fig 6)

A forest plot comparing rate ratios for Sacubitril and Valsartan versus Valsartan alone across various subgroups. Subgroups include age, gender, race, region, diabetic status, LVEF, atrial fibrillation status, NT-proBNP screening levels, SBP at screening, MRA use, ACEI intolerance, baseline eGFR, and NYHA class. Each subgroup's rate ratio estimate with 95% confidence intervals is plotted, indicating the relative effect between the treatments.*

FDA Label Image

656 (Sacubitril Valsartan Fig 7)

A comparative hazard ratio graph for Sacubitril and Valsartan versus enalapril and versus valsartan, plotted against left ventricular ejection fraction at screening (%). The figure shows two panels labeled PARADIGM-HF and PARAGON-HF, each with solid lines representing hazard ratios and dashed lines indicating 95% confidence intervals.*

FDA Label Image

565 (Sacubitril Valsartan Structure)

Chemical structure diagram showing the molecular formula of Sacubitril and Valsartan, the active ingredients in the medication. The diagram includes the detailed atom connectivity and structural arrangement of these compounds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.